TITLE

Allogeneic diabetic mesenchymal stem cells transplantation in streptozotocin-induced diabetic rat

AUTHOR(S)
Qing-Yu Dong; Li Chen; Guan-Qi Gao; Lei Wang; Jun Song; Bo Chen; Yu-Xin Xu; Lei Sun
PUB. DATE
December 2008
SOURCE
Clinical & Investigative Medicine;Dec2008, Vol. 31 Issue 6, pE328
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Bone marrow-derived mesenchymal stem cells (BM-MSCs) are multipotent stroma cells which can provide a potential therapy for diabetes mellitus. But the mechanism is still controversial. Also, the status of BM-MSCs under hyperglycemia is not known. In the present study, we investigated the status of BM-MSCs in experimental-diabetic rat and demonstrated the rescue of experimental diabetes by diabetic MSCs transplantation. Methods: BM-MSCs were cultured and the potential of multiple-differentiation was identified through induction into osteoblasts. MSCs of passage 3 were used for the following experiment. The MSCs were labeled with 5-bromo- 2′-deoxyuridine (BrdU). Diabetes in rats was induced by STZ injection. The rats were divided into three groups: normal control group (no DM, rats treated with saline through tail vein, n=10); DM control group (DM, no transplantation of MSCs, n=20); experimental group (DM and transplantation of MSCs, n=20). Body weight and blood glucose of the rats were monitored during the experiment after transplantation of MSCs. Paraffin sections of pancreas were obtained from rats of each group. Immunohistochemistry analysis and double immunofluorescence were used to detect the BM-MSCs in the pancreatic tissue and their differentiating state. Results: MSCs were 89.5% labeled by BrdU and DAPI, which was green/blue double stained under fluorescent microscopy. Transplantation of diabetic MSCs resulted in a reduction of hyperglycemia on day 45 in experimental diabetic rats compared with control rats (17.7 mM ±3.9 vs 27.8 mM ± 2.1, P < 0.05), There was also a difference between MSC-treated experimental diabetic rats and control rats in body weight (232.7 g ±19.7 vs 133.3g ±13.1, P < 0.05). Histological and morphometric analysis of the pancreas of experimental diabetic rats showed the presence and differentiation of transplanted MSCs into insulinproducing cells which evidenced by double-staining of anti-BrdU and insulin. Also, there were many small islets throughout the sections. Their mean area and diameter analysis revealed that they were smaller thancontrol islets (1835.7 ± 175.8 μm2 vs 13257.2 ± 1457.6 μm2; 43.5 ± 3.7 μm vs 119.9 ± 5.8 μm, respectively, P < 0.05). Conclusion: Allogeneic MSCs transplantation can reduce blood glucose level in recipient rats. A relatively small quantity of transplanted diabetic MSCs survive and transdifferentiate into insulin-producing cells in the pancreas of recipient rats. Upon transplantation these cells initiate endogenous pancreatic regeneration by neogenesis of islet of recipient origin. The present study demonstrates that diabetic MSCs retains its stemness and potential to induce pancreatic regeneration on transplantation.
ACCESSION #
35765179

 

Related Articles

  • Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes. Diao, Teng-Yue; Pan, Hai; Gu, Sa-Sa; Chen, Xi; Zhang, Fang-Yi; Wong, Man-Sau; Zhang, Yan // Journal of Bone & Mineral Metabolism;May2014, Vol. 32 Issue 3, p261 

    There are contradictory results about the effect of angiotensin-converting enzyme inhibitors (ACEIs) on bone. This study was performed to address the skeletal renin−angiotensin system (RAS) activity and the effects of the ACEI, captopril, on the bone of streptozotocin-induced type 1...

  • Nature Genetics: A new approach to treating type I diabetes? Gut cells transformed into insulin factories.  // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1 

    The article focuses on a new study led by Columbia researchers which suggests the use of patient's intestinal cells in making insulin for treatment against type I diabetes and use of this insulin as a replacement of stem cell replacement therapy.

  • Tell Me More. Mettenburg, Julie // Countdown;Winter2000, Vol. 21 Issue 1, p40 

    Provides answers to readers' questions about diabetes. Barriers in the consideration of stem cell transplantation as a possible cure for diabetes; Research about genes called HLA markers which are associated with risk for diabetes.

  • C3-C4 shingles post haematopoietic stem-cell transplantation. Connor, Siobhan; O'Brien, Mairead; Irvine, Alan; O'Marcaigh, Aengus; Smith, Owen // Archives of Disease in Childhood;Feb2015, Vol. 100 Issue 2, p137 

    The article presents a case study of a boy with pruritic right sided C3-C4 shingles developed due to unrelated haematopoietic stem-cell transplantation (HSCT) for relapsed acute myeloid leukaemia. He developed full C3-C4 dermatome skin erosion to the dermis with secondary hair loss extending to...

  • Breakthrough in Stem Cell Therapy.  // India -- West;7/16/2010, Vol. 25 Issue 34, pA41 

    The article reports on the success of an autologous stem cell-based therapy procedure in a nine-month-old dog conducted by researchers at Tamil Nadu Veterinary and Animal Sciences in India.

  • Carboplatin/etoposide: Intrapulmonary haemorrhage: case report.  // Reactions Weekly;Jun2019, Vol. 1756 Issue 1, p96 

    A 71-year-old woman developed pruritus and acneiform skin rash during treatment with erlotinib for lung adenocarcinoma. Additionally, the acneiform skin rash and pruritus worsened following concomitant administration of erlotinib and aprepitant for lung adenocarcinoma.

  • Amelioration of Streptozotocin-Induced Diabetes in Mice with Cells Derived from Human Marrow Stromal Cells. Min Zhao; Amiel, Stephanie A.; Ajami, Sanaz; Jie Jiang; Rela, Mohamed; Heaton, Nigel; Guo Cai Huang // PLoS ONE;2008, Vol. 3 Issue 7, p1 

    Background: Pluri-potent bone marrow stromal cells (MSCs) provide an attractive opportunity to generate unlimited glucose-responsive insulin-producing cells for the treatment of diabetes. We explored the potential for human MSCs (hMSCs) to be differentiated into glucose-responsive cells through...

  • Hope For a Type 1 Diabetes Cure?  // Diabetes Health;Jun/Jul2007, Vol. 16 Issue 3, p19 

    The article discusses research being done on the effectiveness of the procedure called autologous nonmyeloablative hematopoietic stem cell transplantation (AHST) in treating type 1 diabetes. It references a study by researchers from Sao Paulo, Brazil, published in the April 2007 issue of the...

  • Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Beilhack, Georg F.; Scheffold, Yolanda C.; Weissman, Irving L.; Taylor, Cariel; Jerabek, Libuse; Burge, Matthew J.; Masek, Marilyn A.; Shizuru, Judith A. // Diabetes;Jan2003, Vol. 52 Issue 1, p59 

    Purified hematopoietic stem cells (HSCs) were transplanted into NOD mice to test whether development of hyperglycemia could be prevented. Engraftment of major histocompatibility complex-mismatched HSCs was compared with bone marrow (BM) grafts. HSCs differed from BM because HSCs were more...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics